In the SERENA‐2 trial, camizestrant, a next‐generation oral selective estrogen receptor antagonist and degrader (ngSERD), is being studied with promising results in post‐menopausal women with advanced ER‐positive/HER2‐negative BC. The gene discussed is ESR1; the disease is breast cancer.